About Us
Science
Technology
Services
News
Contact us

About us

Our Story

How we were created

MSInsight was founded in 2022 by a team of leading physicians, biologists, and engineers from Paris hospitals, Inserm, and Sorbonne University. Our journey began with a commitment to transforming cancer care through precision diagnostics. We recognized a critical gap in accurately diagnosing microsatellite instability (MSI), a key cancer biomarker.

With 20 years of research, our flagship product, MSIcare, delivers precise diagnostics, offering patients tailored treatment plans and improved outcomes. Recognized for our innovation, we continue to advance cancer care with cutting-edge technology and a commitment to excellence.

Who Are We

MSInsight is a start-up company, dedicated to advancing precision cancer treatment through innovative biomarker detection. We specialize in detecting specific biomarkers to enable more effective and personalized cancer care.

 

Our proprietary software, MSIcare, harnesses next-generation sequencing technology to detect microsatellite instability (MSI) in solid tumors and liquid biopsies. MSI is a key marker of DNA repair system dysfunction, known as mismatch repair deficiency, which impacts how well patients may respond to certain precision treatments.

 

MSInsight offers expert data analysis services to identify microsatellite instability, supporting healthcare providers with vital insights for personalized treatment planning.

Our Story

How we were created

Our Core Values

They guide every aspect of our work

MSInsight was founded in 2022 by a team of leading physicians, biologists, and engineers from Paris hospitals, Inserm, and Sorbonne University. Our journey began with a commitment to transforming cancer care through precision diagnostics. We recognized a critical gap in accurately diagnosing microsatellite instability (MSI), a key cancer biomarker.

With 20 years of research, our flagship product, MSIcare, delivers precise diagnostics, offering patients tailored treatment plans and improved outcomes. Recognized for our innovation, we continue to advance cancer care with cutting-edge technology and a commitment to excellence.

Outline of a family with pink and blue gradient colors.

Patient Centric

Outline of a cartoon head with gears turning inside colored with pink and blue gradient.

Expert Knowledge

Outline of two hands shaking. This shows collaboration and partnership.

Collaboration

MEET OUR TEAM

At MSInsight, we bring together a team of dedicated experts in genomics, bioinformatics, and oncology.

Arnaud Cutivet, CEO of MSInsight

Arnaud Cutivet, PhD

CEO
Toky Ratovomanana, CTO of MSInsight. Professional photo.

Toky Ratovomanana, PhD

CTO
Alex Duval, CSO of MSInsight. Professional photo

Alex Duval, MD-PhD

CSO
Olivier Exertier, CFO of MSInsight. Professional photo.

Olivier Exertier, eMBA

CFO
Florance Renaud, medical advisor for MSInsight. Professional photo

Florence Renaud, MD-PhD

Medical Advisor
Ada Collura, scientific advisor for MSInsight. Professional photo

Ada Collura, PhD

Scientific Advisor

OUR MAIN PARTNERS

Pleased to work with:

THEY SUPPORT US

We are backed by renowned start-up programs, institutions, and public initiatives!

Get notified when the software is available

MSInsight
64 avenue Pierre Grenier
92100 Boulogne-Billancourt

55 ter Avenue René Cassin
69009 Lyon

Contact

contact@msinsight.tech

Copyright 2023 © MSInsight. All rights reserved
Arnaud Cutivet, CEO of MSInsight

Arnaud Cutivet

Chief Executive Officer

Before founding MSInsight, Arnaud served as the Deputy Director of the Cancer Cluster CLARA. He facilitated numerous technology transfer projects in oncology with biotech and medtech startups, and led several strategic partnerships with pharmaceutical laboratories. Notably, he successfully managed grants totaling €8 million. 

Earlier in his career, Arnaud led innovation at Indicia Biotechnology, an immunotechnology services company. Arnaud holds an engineering degree from ENSICAEN and a PhD in biotechnology from UTC. 

As CEO of MSInsight, Arnaud oversees the company’s development and management strategy, as well as business development.

Linkedin

Dr. Toky Ratovomanana

Chief Technical Officer

Toky possesses expertise in bioinformatics and genomics, specializing in the application of IT and programming to enhance genomic research. 

His focus is on the integration of bioinformatics tools and machine learning for analyzing cancer genetics, notably microsatellite instability. Actively involved in research and development in oncology genomics, he demonstrates proficiency in high-throughput genomics, single-cell analysis, and leveraging deep learning for gene expression analysis.

His research aims at improving the predictability of treatment responses in colorectal and breast cancer, striving to identify novel biomarkers and facilitate biological interpretations of AI models. 

His work was awarded by the « Pépite » national contest and the French Society of Personalized Medicine. 

In 2022, he co-founded MSInsight and acts as Chief Technical Officer.

Linkedin
Alex Duval, CSO of MSInsight. Professional photo

Pr. Alex Duval

Chief Science Officer

Alex is a full professor of medicine at Sorbonne University, specialized in Cancer Genetics. He has been directing an Inserm team for over 18 years in Paris with research activity dedicated to MSI cancers. 

As a medical doctor, he heads the MSI precision medicine cancer diagnostics laboratory at the La Pitié-Salpêtrière Hospital, Paris. He is an internationally recognized opinion leader regarding the personalized care of these tumors. Translational genomic research activities aim at discovering new risk factors, biomarkers, and diagnostic tools, some of which have been patented, licensed, and used in routine clinics.

He has over 120 publications and 10 patents. 

At MSInsight, he is in charge of our scientific programs.

Link
Olivier Exertier, CFO of MSInsight. Professional photo.

Olivier Exertier

Chief Financial Officer

Olivier holds an Executive Health MBA. 

A manager specialized in the healthcare sector, he spent more than 15 years working as a senior manager in management consulting, in charge of a business unit dedicated to life science (Algoé Consultants). Consequently, he has supported numerous entrepreneurial and innovation projects in oncology and infectiology. 

He served as the Director of the Cancer Cluster CLARA for 4 years before joining the Director’s Office of the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO). 

Additionally, Olivier is a member of an investment fund in life sciences. 

At MSInsight, he is in charge of the financial management and fund-raising.

 

Linkedin
Florance Renaud, medical advisor for MSInsight. Professional photo

Dr. Florence Renaud

Medical Advisor 

Within Paris Hospital, Florence is an anatomopathologist specialized in MSI diagnosis. Her scientific interests lie in digestive oncology, digestive pathology, molecular biology, and digital pathology. She also holds a position as an associate professor at Sorbonne University. 

At MSInsight, she plays a key role in shaping the company’s medical strategy.

Link
Ada Collura, scientific advisor for MSInsight. Professional photo

Dr. Ada Collura

Scientific Officer

Ada holds a Ph.D. in Genetics from the University of Paris Sud. She is currently a Research Associate and conducts her research activities within an Inserm team at Saint-Antoine Research Center. 

At MSInsight, she is involved in our scientific strategy and the implementation of our R&D programs.

Linkedin Link